Bioventus Reaches Milestone with 2 Million DUROLANE® Treatments Worldwide
22.9.2020 17:30:00 EEST | Business Wire | Press release
Bioventus, a global leader in Innovations For Active Healing, is celebrating a milestone and recognizing more than 2 million treatments worldwide with DUROLANE, its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). DUROLANE is the original single injection hyaluronic acid therapy, has helped patients in nearly 30 countries and is a trusted therapy for clinicians in the management of OA.
Proven safe and effective, DUROLANE has more clinical studies than any other US single-injection HA, and has also been proven to provide greater reduction in OA knee pain versus Synvisc-One®.1,2 It has longer lasting pain relief versus a steroid injection, is safe and repeated use of DUROLANE does not increase the incidence of adverse events.3,4
DUROLANE is available in its original 3ml syringe for treatment of large joints and in a 1ml syringe, known as DUROLANE SJ, to enable treatment of small joints.* Both are produced using a natural, safe and proven technology called NASHA ® . This process yields a high molecular weight stabilized HA, which is a naturally occurring molecule that provides lubrication and cushioning in a normal joint.
“The US launch of DUROLANE in 2018 boosted our growth to more than 2 million treatments and we are very proud of this milestone. Still, there are many more patients to reach,” said John Nosenzo, Chief Commercial Officer, Bioventus. “In the US, more than 14 million people are afflicted with knee OA and osteoarthritis overall affects more than 240 million globally.5,6 Returning people to active lifestyles is our commitment to the market and we are pleased that DUROLANE is serving the needs of clinicians and the OA patients they treat.”
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the company on LinkedIn and Twitter.
Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
*DUROLANE SJ is not available in the US.
Summary of Indication for Use: DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen. Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Full prescribing information can be found in product labeling, at www.DUROLANE.com , or by contacting Bioventus Customer Service at 1-800-836-4080.
NOTE: The above indications presented are for the US market; indications may vary by country. Contact your local Bioventus representative or visit www.durolane.com/uk/selection for prescribing information specific to your market.
1. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 2. DOF RPT-001111 3. Leighton R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2017. 5. Arthritis Foundation. What is osteoarthritis? Accessed February 9, 2019. www.arthritis.org/about-arthritis/types/osteoarthritis/what-is-osteoarthritis.php 6. Hawker GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol. 2019;37 Suppl 120(5):3-6.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005067/en/
Contact information
Thomas Hill
919-474-6715
thomas.hill@bioventusglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results13.8.2026 13:30:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the second quarter of fiscal year 2026 (the three months ended June 30, 2026) and the first half of fiscal year 2026 (the six months ended June 30, 2026). Second Quarter 2026 Financial Highlights Total revenues were $49 million, an increase of 13% year-over-year. Net income attributable to SBC Medical was $11 million, an increase of 335% year-over-year. Net income margin was 22%, an increase of 16 percentage points year-over-year. Adjusted EBITDA1 was $20 million, an increase of 32% year-over-year. Adjusted EBITDA margin1 was 41%, an increase of 6 percentage points year-over-year. Basic EPS was $0.10 for the three months ended June 30, 2026, an increase of 400% year-over-year. The Company believ
Unimed Expands Maritime Healthcare Platform with Growing Adoption of Telemed Plus13.8.2026 12:00:00 EEST | Press release
Universal Maritime Solutions (“Unimed” or “the Company”), a leading provider of maritime healthcare, medical supply, and crew wellbeing solutions and a portfolio company of ZCG Private Equity, the private equity fund management platform of Z Capital Group, LLC (“ZCG”), today announced that Bahri, one of the Middle East’s leading maritime operators, has expanded its relationship with Unimed by enrolling in its Telemed Plus premium service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813787745/en/ The agreement builds on a longstanding relationship between the companies through Unimed’s MedScale medical supply and medical chest management program and marks another important milestone in the continued rollout of Unimed’s Telemed Plus platform, launched in 2024. The expansion underscores the growing adoption of Unimed’s integrated healthcare platform by leading global maritime operators while demonstrating the increasing v
The Fairest of Them All: Klarna Supercharges Memberships, Removing Fees, Boosting Cashback and Increasing Annual Value to as Much as €6,00013.8.2026 10:09:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, today unveiled its most significant membership upgrade yet. The revamped tiers deliver more cashback, up to €6,000 worth of perks, and remove service fees — built so a Klarna membership pays for itself, and then some. Klarna's improved membership lineup spans four tiers, each built for a different kind of member but all embodying a flexible ethos: pay only for the Klarna that fits your life. Pay later is free at partner stores, or get broader fee-free access with Everywhere (formerly Core), or climb to Plus, Premium or Max for richer cashback rewards, bigger, everyday perks and a growing set of subscriptions and protections. A Klarna membership is a fairer alternative to a credit card by design, and one of the biggest differences is freedom. While other cards tie you in for a year, a Klarna membership moves with you. Upgrade for a big travel month and drop back down when things are quieter, with no penalty and no year-long
Interactive Brokers Adds Access to the Bucharest Stock Exchange, Offering Access to One of Europe's Strongest-Performing Markets of 202513.8.2026 10:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced access to the Bucharest Stock Exchange (BVB). This expansion offers access to one of Europe’s strongest-performing emerging markets of 2025, expanding diversification opportunities for IBKR clients alongside over 170 other global exchanges on a single, advanced platform. Romania was elevated to MSCI’s Advanced Frontier Market status while the BET index reached record highs in 2025 and continued its growth through the first half of 2026. With this integration, IBKR clients can access Romanian equities through the same platform they use for markets worldwide, making it easier to incorporate Romanian listed companies into their global investment strategies. “Adding the Bucharest Stock Exchange expands the choices available to our clients and reinforces our commitment to providing the broadest possible access to global markets,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “Romania is one o
Lenovo Group: Q1 Financial Results 2026/2713.8.2026 07:16:00 EEST | Press release
Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported first quarter results for fiscal year 2026/27, marking the highest quarterly revenue growth in the past five years and the strongest quarter in the Group’s history. During the quarter, overall Group revenue reached an all-time quarterly high of US$26.9 billion, up 43% year-on-year, with all business groups delivering record first-fiscal-quarter revenue and operating profit. Adjusted net income[1]was up 176% year-on-year to US$1.1 billion, surpassing the US$1 billion milestone for the first time ever, with adjusted net margin improvements of almost two percentage points year-on-year supported by higher revenue scale and continued efficiency gains. AI-related revenue[2] grew 60% year-on-year to US$9.3 billion, accounting for 35% of total Group revenue in Q1. The Group continues to invest in innovation with R&D expenses up 30% year-on-year. The first quarter results demonstrate the G
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom